BriaCell Therapeutics Corp.
As of Oct 22, 2026, BriaCell Therapeutics is in Stage 1, the basing phase, now in week 9 (since Aug 21, 2026). It closed at $3.41, 75.3% below its 52-week high and below its 200-day average, which is falling.
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is BCTX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
BCTX among Biotechnology436th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …436 | BCTX | Stage 1 · wk 9 | 14 | −15.0% |
BriaCell Therapeutics: quick answers
What stage is BriaCell Therapeutics in?
As of Oct 22, 2026, BriaCell Therapeutics (BCTX) is in Stage 1, the basing phase. It entered Stage 1 on Aug 21, 2026 and is in week 9. What the four stages mean
Is BriaCell Therapeutics in an uptrend?
Not yet. BriaCell Therapeutics is in Stage 1, a base that can come before an uptrend. It trades 13.4% below its 200-day average, which is falling.
How far is BriaCell Therapeutics from its 52-week high?
BriaCell Therapeutics closed at $3.41 on Oct 22, 2026, 75.3% below its 52-week high of $13.79. Its 52-week low is $2.74.
How has BriaCell Therapeutics performed over the past year?
As of Oct 22, 2026, BriaCell Therapeutics is down 73.3% over the past year and down 52.4% so far in 2026.
Which sector and industry is BriaCell Therapeutics in?
BriaCell Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.